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Endoscopic double stenting for the treatment of 
malignant biliary and duodenal obstruction due to 
pancreatic cancer
Background In non resectable pancreatic cancer 
cases found to have duodenal stenosis, 13-20% are in the 
terminal stage when obstruction occurs. Considering 
the systemic condition and limited prognosis, it is better 
to apply minimally invasive treatment whenever possible.
Recently, endoscopic duodenal stenting DuS , which is 
also minimally invasive, is being increasingly used. In 
addition, it is referred to as double stenting, combining 
biliary stenting BS  and DuS, and it has also been 
reported. The purpose of the present study was to retro-
spectively evaluate endoscopic double stenting by endo-
scopic retrograde cholangiopancreatography-guided bili-
ary  dra inage  ERCP-BD  and by  endoscop ic 
ultrasono graphy-guided biliary drainage EUS-BD  for 
the treatment of non-resectable malignant biliary and du-
odenal obstruction.
Patients and Methods Medical records of 11 pa-
tients that underwent endoscopic double stenting from 
January 2008 to September 2012 were analyzed retro-
spectively.
Results Technical success rate was 100%, clinical 
success rate was 100%, early complication rate was 0% 
and late complication rate was 27.3% cholangitis : two, 
perforation : one . Mean survival time from double 
stenting was 76.5 67.8 days, mean patent period of the 
duodenal stent was 73.5 69.7 days, and mean patent 
period of the biliary stent was 62.6 60.4 days. Three 
